Asia-Pacific Region Vies For Biotechnology Industry Opportunities 20/06/2013 by Daria Kim for Intellectual Property Watch Leave a Comment Hong Kong – A recent conference here looked at the evolving biotechnology landscape in the Asia-Pacific region as well as prospects for networking and raising capital for early stage life science innovation.
New Draft Text Issued By WIPO Negotiators For Visually Impaired Treaty 19/06/2013 by William New, Intellectual Property Watch 1 Comment World Intellectual Property Organization delegates this week have launched into negotiations expected to yield the first treaty creating exceptions and limitations to copyright for the benefit of visually impaired people. Many delegations have said much work remained to be done in the next ten days to breach differences. A new text was released this evening on commercial availability.
European Commission Fines Pharma Companies For Payments To Delay Generic Entry 19/06/2013 by Brittany Ngo for Intellectual Property Watch 1 Comment The European Commission (EC) has fined Danish pharmaceutical company Lundbeck as well as eight other generic manufacturers for delaying market entry of generic medicines by way of patent settlement agreements (also known as “pay-for-delay” agreements).
The Impact Of Derailing The WHO Medical R&D Convention 19/06/2013 by Intellectual Property Watch 1 Comment An article in the newly launched Journal of Health Diplomacy about the stalled progress at the World Health Organization for a medical research and development (R&D) convention discusses systemic failures in global health policy.
EIFL Guide To The European Orphan Works Directive 19/06/2013 by Intellectual Property Watch Leave a Comment A guide to key provisions and limitations of the European Union directive on permitted uses of orphan works – those whose creators cannot be found – has been published by the Electronic Information for Libraries (EIFL).
WIPO Seminar Discusses Impact Of TRIPS On Pharmaceutical Innovation 19/06/2013 by Brittany Ngo for Intellectual Property Watch Leave a Comment The latest instalment of the World Intellectual Property Organization seminar series titled “The Economics of Intellectual Property” covered the issue of product patents in the pharmaceutical industry. Discussion focussed on the economics of intellectual property rights and how pharmaceutical patent protection might not be the sole culprit in the access to innovation problem.
Good Intentions Echo In Marrakesh At Start Of Negotiations On Treaty For The Blind 18/06/2013 by Catherine Saez, Intellectual Property Watch Leave a Comment The World Intellectual Property Organization diplomatic conference expected to yield a treaty creating exceptions and limitations to copyright for the benefit of visually impaired people opened today in Marrakesh, Morocco. Assurances of good faith and willingness to find solutions for remaining issues were given by delegates, while WIPO Director General Francis Gurry called for unity, King Mohammed VI talked about moral obligation in a royal message, and visually impaired people called for negotiators to create history. All nonetheless agreed on the importance of the copyright system.
US Supreme Court Rules On Pharma Payments To Delay Generic Drugs On Market 17/06/2013 by Catherine Saez, Intellectual Property Watch Leave a Comment The United States Supreme Court in a five to three decision today found that settlement agreements by branded pharmaceutical companies involving payments to generic companies to delay their cheaper drugs’ entry into the market may not be immune from antitrust scrutiny but are not “presumptively” unlawful. The case was sent back to lower court.
US Supreme Court Restricts Gene Patents … A Little 17/06/2013 by Steven Seidenberg for Intellectual Property Watch 2 Comments Last Thursday, the United States Supreme Court overturned more than 30 years of precedents and ruled that isolated genes cannot be patented. They are products of nature and thus not patent-eligible subject matter, the court unanimously held in Assoc. for Molecular Pathology v. Myriad Genetics, Inc. This ruling puts the US at odds with most other nations, which allow genes to be patented. But because other major nations grant narrower gene patents, the net effect of Myriad will be to shift the US position on gene patents closer to that of other nations.
Group Of Experts Looks At High Price Of Cancer Drugs 17/06/2013 by Intellectual Property Watch Leave a Comment Prices of cancer drugs must be lowered to be affordable for patients and to maintain sound long-term healthcare policies, according to a group of chronic myeloid leukemia (CML) experts in a recent Blood journal editorial.